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Abstract.  The tumor suppressing capacity of the 
retinoblastoma protein (p110  Ra) is dependent on inter- 
actions made with cellular proteins through its 
carboxy-terminal domains.  How the pll0  RB amino- 
terminal  region contributes to this activity is unclear, 
though evidence now indicates it is important  for 
both growth suppression and regulation of the full- 
length protein.  We have used the yeast two-hybrid sys- 
tem to screen for cellular proteins which bind to the 
first 300 amino acids of pll0 ~. The only gene iso- 
lated from this screen encodes a novel 84-kD nuclear 
matrix protein that localizes to subnuclear regions 
associated with RNA processing.  This protein,  p84, 
requires a  structurally defined domain in the amino 
terminus of pll0  ~  for binding.  Furthermore,  both in 
vivo and in vitro experiments demonstrate that p84 
binds preferentially to the functionally active, hypo- 
phosphorylated form of p110  RB. Thus, the amino ter- 
minus of pll0  RB may function in part to facilitate the 
binding of growth promoting factors at subnuclear 
regions actively involved in RNA metabolism. 
M 
UTATIONAL inactivation  of  the  retinoblastoma 
(RB) I susceptibility gene has been found in a va- 
riety  of human  neoplasms;  cells  derived  from 
these  tumors  consistently  display  reduced  tumorigenicity 
following  reintroduction  of a wild-type RB allele demon- 
strafing the tumor suppressing ability of the encoded protein 
(Bookstein  and Lee,  1991). Growth suppression  assays of 
cultured cells suggest that the COOH-terminal half of the 
retinoblastoma protein is sufficient for this function. Specifi- 
cally, microinjection of an amino-terminally  truncated form, 
p56  ~,  into  cells early  in  the  GI  phase  of the cell  cycle 
blocks  their  progression  into  S  phase  (Goodrich  et  al., 
1991).  These  results  were  confirmed  in  an  independent 
growth  retardation  assay  (the  "flat  cell  assay")  following 
transfection  of various  RB constructs  (Qin  et al.,  1992). 
While these experiments  establish the growth  suppressing 
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capabilities of the RB protein, a concise mechanistic picture 
of how this occurs remains elusive. 
The RB gene product (pll0  ~) is a  ll0-kD nuclear pro- 
tein (Lee et al., 1987) that is phosphorylated on both serine 
and threonine  residues (Buchkovich et al., 1989; Ludlow et 
al., 1989; Shew et al.,  1989). These modifications occur in 
a  cell  cycle-dependent manner  (Buchkovich  et al.,  1989; 
Chen et al., 1989; DeCaprio et al., 1989), and are hypothe- 
sized to be important  in negatively  regulating  the protein. 
During the G1 phase of the cycle, pll0  RB is hypophosphor- 
ylated and in an active state.  At some point later in Gt, it 
becomes hyperphosphorylated, likely by a member of the 
CDK family of kinases (l.e,  es et al., 1991; Lin et al., 1991), 
inactivating  its  growth  suppressing  function(s).  Dephos- 
phorylation of the RB protein occurs during  mid-M phase, 
activating the protein prior to the next cell cycle. Evidence 
strongly implicates the type 1 protein phosphatase as being 
critical  for this process (Alberts et al.,  1993; Durfee et al., 
1993; Ludlow et al.,  1993). 
The RB protein is also known to bind the oncoproteins of 
several  DNA tumor viruses:  the adenovirus  E1A protein 
(Whyte  et  al.,  1988),  the  SV-40 large  T-antigen (T-ag) 
(DeCaprio et al., 1988), and the HPV E7 protein (Dyson et 
al., 1989). All three of these viral oncoproteins bind prefer- 
entially  to the hypophosphorylated isoform of p110  R~ 0mai 
et al.,  1991; Ludlow et al.,  1989; Templeton  et al.,  1991), 
and require regions of pll0  RB for binding which are affected 
by most known  naturally  occurring mutations  (Hu et al., 
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mains, the T/EtA domains, lie near the carboxy-terminal 
portion of the molecule, and are necessary for the growth 
suppressing activity of the protein. Although precisely how 
these domains function is unclear, they are required for inter- 
acting with a variety of cellular proteins in complexes be- 
lieved to be essential for the growth-suppressing activity of 
the RB protein (for review see Goodrich and Lee, 1993). 
Like many other nuclear antigens, p110  RB is concentrated 
in multiple foci in the nuclei of intact cells (Szekely et al., 
1991; Mancini, M. A., and W.-H. Lee, unpublished results). 
The highest concentrations of pll0  ~  exist in regions of low 
DNA density (actively transcribed euchromatin) (Szekely et 
al.,  1991). This heterogeneous distribution suggests that a 
structure exists  for spatially organizing pll0  ~  within the 
nucleus. The best candidate for such a structure is the nu- 
clear matrix, biochemically and morphologically defined as 
the chromatin-free, insoluble framework of the nucleus. It is 
upon this scaffolding  that many functional subdomains of the 
nucleus are organized, including those involved in replica- 
tion, RNA transcription and splicing (Jackson and Cook, 
1988;  Nickerson et al.,  1993;  Carter et al.,  1992,  1993). 
Hypophosphorylated pll0  ~  has also been shown to "tether 
to the nuclear structure" (Mittnach and Weinberg, 1991), and 
in fact, under more rigorous conditions can be shown to as- 
sociate with the nuclear matrix (Mancini et al.,  1994).  In- 
terestingly, the three viral oncoproteins which interact with 
pll0  ~  are also found in association with the nuclear matrix 
(Chatterjee and Flint, 1986; Greenfield et al., 1991; Schrim- 
beck and Deppert,  1989).  The fact that matrix association 
is specific for the active isoform of pll0  ~, and is abolished 
by naturally occurring RB mutations, argues that the protein 
may normally function, at least in part, within the architec- 
tural framework of the nucleus (Mancini et al., 1994; Mitt- 
nach and Weinberg,  1991; Templeton et al.,  1991). Cur- 
rently, the mechanism by which pll0  aB associates with the 
nuclear matrix is poorly understood,  although anchoring 
through interaction with matrix proteins is a strong possibil- 
ity. pll0  R8 has been shown to bind lamins A and C in vitro 
(Mancini et al.,  1994;  Shah et al., 1992),  which may con- 
tribute to the preferential binding of hypophosphorylated 
pll0  ~  to isolated nuclear shells (Templeton,  1992).  How- 
ever, as the spatial distribution of nuclear matrix-associated 
pll0  ~B is more widespread than that of the lamins (Mancini 
et al., 1994),  it seems certain that the RB protein will inter- 
act with additional nuclear maatrix factors, perhaps also in 
a region-specific manner. 
Whereas carboxy-terminal domains of p110  ~  are clearly 
important in growth suppression (Goodrich et al., 1991; Qin 
et al.,  1992),  evidence pointing to a functional role for the 
amino-terminal region in this process is only now emerging. 
First, small deletions affecting the amino-terminal segment 
of pll0  ~  block  the  ability  of transfected RB  to  inhibit 
growth in the fiat cell assay (Qian et al., 1992; Hinds et al., 
1992). Interestingly, these mutants do not qualitatively  block 
the ability of the resultant RB protein to bind the transcrip- 
tion factor E2F, or the EtA protein (Qian et al., 1992), indi- 
cating an additional activity is required. More recently, a RB 
mutation has been isolated from a  retinoblastoma tumor, 
which is predicted to specifically remove only exon 4 (amino 
acids 126-166) (Hogg et al., 1993). This is the first example 
of a clinical specimen With an inactivating mutation affecting 
only the amino-terminal domain. Structurally, two protease- 
resistant domains reside in this region of the protein, some 
portion of which can physicallY interact with the carboxy- 
terminal  half of pll0  ~8  (Hensey  et  al.,  1994).  Deletion 
studies  also  indicate  that  amino-terminal  sequences  are 
necessary for the hyperphosphorylation of the full-length 
molecule (Hamel et al.,  1990;  Qian et al.,  1992;  Hinds et 
al., 1992).  It is not clear, however, whether this is due to a 
structural defect, or the loss of important cdc2 sites located 
therein (Lees et al., 1991; Lin et al., 1991). The severe func- 
tional and structural consequences of amino-terminal muta- 
tions clearly demonstrate the importance of this domain in 
the context of native pll0  ~, and warrant further investiga- 
tion into the activity of this part of the molecule. 
Evidence now suggests that the RB protein exerts its func- 
tion through  interaction with other  cellular proteins.  To 
ascertain whether cellular proteins capable of binding to the 
pll0  ~  amino terminus exist, we conducted a screen using a 
modified version of the yeast two-hybrid system (Fields and 
Song, 1989; Durfee et al., 1993). This and other variations 
have proven effective in isolation of interacting proteins from 
cDNA expression libraries in the yeast S. cerevisiae (Chien 
et al.,  1991; Dalton and Treisman,  1992;  Durfee et al., 
1993;  Yang et al.,  1992).  The only gene isolated from this 
screen encodes a novel nuclear matrix protein which inter- 
acts specifically with the amino-terminal region of hypo- 
phosphorylated  pll0  RB.  This  protein,  p84,  localizes  to 
regions of the nucleus known to be sites of RNA processing. 
This  interaction may provide  a  link between pll0  ~  and 
RNA processing centers in the nucleus. 
Materials and Methods 
Strains and Media 
E. coli DH5 (F-, recAl, endAl, hsdRl7, supE44, thil, gyrA, re/A1) was the 
transformation recipient for all plasmid constructions. JA226 (hsdR, hsdM, 
leuB6, Iopll,  thi,  recBC, strR)  (the gift of M. Hoerkstra, ICOS, Seattle, 
WA) was used to recover expression plasmids from yeast. The E. coil B 
strain BL21-LysS (Studier et al., 1990) was used for the expression of GST 
fusion proteins.  Y153,  MATc~ leu2-3,112, ura3-52,  trpl-901, his3-A200, 
ade2-101, gal4A, gal8OA, URA3  : :GAL-IacZ, LYS2  :  :GAL-HIS3 was the yeast 
strain used in all experiments. 
For drug selections, LB plates were supplemented with ampieillin (50 
/~g/ml). Minimal media plates for E. coil, lacking leucine and containing 
ampicillin, were prepared as described (Miller,  1972).  Yeast YEPD and 
synthetic complete (SC)  media was prepared as described (Rose et al., 
1990). 
Plasmids 
pAS/N-RB construction was described in Durfee et al. (1993). pAS/N-HBg 
was generated by digesting BKS/N-RB (Durfee et al.,  1993)  with HpaI, 
ligating with  12-bp BglH linkers (New England Biolabs, Beverly,  MA), 
recleaved with BglII, and self ligating. The BamHI-SalI fragment was then 
ligated into pAS1 (Durfee et al.,  1993).  pAS/N-EBg was constructed by 
digesting pRB-N with EcoRV, and repeating the same steps with the BglII 
linker as pAS/N-HBg. Details of the remainder of the deletion series con- 
struction are available upon request. 
Library Screening and Plasmid Recovery 
Screening was performed as described in Durfee et al. (1993). Briefly, Y153 
was transformed to Trp  prototrophy with pAS/N-RB by the method of 
Schiestl and Gietz (1989).  A single colony was grown in SC-trp media and 
transformed with library DNA using total yeast RNA as carrier. The mix 
was then plated on 15 cm petri dishes containing SC media lacking trypto- 
phan, leucine and histidine but including 25 mM 3-aminotriazole (3-AT; 
Sigma Chemical Co.), and incubated at 30°C for 3-5 d.  His  + colonies 
were then screened for ~-galactosidase activity using a  filter lift assay 
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color development ranged from 30 min to overnight. Colonies correspond- 
ing to positives in this screen were then patched onto a master plate and 
further analyzed. 
Total DNA from yeast was prepared using the method of Hoffman and 
Winston (1987), and used to transform JA226 via electroporation using a 
BioRad GenePulser according to the manufacturer's specifications. Trans- 
formation were plated on minimal media lacking leucine and containing 
ampicillin. 
Quantitation of  ~-Galactosidase Activity in Yeast 
2.5 ml cultures were grown in the appropriate selecting media to ODt00 
1.0-1.2.  Ceils  were  then  prepared  and  permeabilized  as  described 
(Guarente,  1983).  For qnantitation the  same  procedure  as  in Guarente 
(1983) was followed except cell pellets were resuspoaded in 900 ml H buffer 
(100 mM Hepes,  150 mM NaCI, 2 mM MgC12,  1% BSA, pH 7.0),  100 ml 
50 mM chlorophenyl-red-b-o-galactopyranoside (CPRG; Boehringer Mann- 
heim Biochemicais, Indianapolis, IN) was added following permeabiliza- 
tion, and the amount of liberated CPR was determined by OD~74. 
Sequence Analysis 
Clones were sequenced using dideoxy-NTPs and Sequenase 2.0 according 
to the manufacturer's specifications (United States Biochemical, Cleveland, 
OH).  Sequence  analysis and homology  searches  were  performed  using 
DNASTAR software (DNASTAR,  Inc., Madison, WI). 
Construction of GST Fusions, Protein Preparation, 
and In Vitro Binding 
To construct GST-N5, the N5 yeast plasmid was digested with BglII and the 
0.9-kb  insert fragment  subcloned  into the  BamHI  site pGEX-3X.  One 
resulting clone had the N5 eDNA insert in reverse orientation with respect 
to the GST coding sequences, and was designated GST-R5N. GST-Tag has 
been described previously (Durfee et al.,  1993). Expression of proteins in 
E.  coli, and in vitro assays were identical to those in Durfee (1993). 
Antibody Preparation, Eukaryotic Cell Extracts, and 
Protein Detection 
Antisera were raised in female BALB/c mice injected subcutaneously with 
80/~g GST-N5 bound to glutathione beads in 75/zl sterile PBS. Mice were 
boosted with 100 #g GST-N5/beads after 2 wk and again after 2 mo. An 
additional boost was given 6 wk later, 3 d before spleenic fusion with NS1 
cells  (American Type Culture Collection,  Rockville,  MD)  according to 
standard protocol. Fus.ed cells were screened by ELISA against GST-N5 or 
GST. After three rounds of screening for N5-specific clones, supernatants 
were collected, evaluated by immunoblotting and immunostaining, and then 
frozen at -80°C.  5El0 was the most reactive clone and was subsequently 
single cell cloned. 
For antibody preparations which were preabsorbed before use, 10 #g of 
the appropriate GST fusion protein was incubated with 1 #g of antibody se- 
rum in 250 buffer (50 mM Tris, pH 7.4, 250 mM NaC1, 5 mm EDTA, 0.1% 
NP-40,  50 mM NaE  1 mM PMSE  1 ~g leupeptin per ml,  1 /zg antipain 
per ml) for 60 min at 40C. Glutathione-coated Sepharose beads were added, 
and the mix incubated for an additional 30 min at 4°C while rotating. Fol- 
lowing centrifugation, the supernatant was used for immunoprecipitation. 
Yeast cell extracts were prepared by growing 5 ml of cells to stationary 
phase under the appropriate selecting conditions. Cells were then pelleted 
by centrifugation, and lysed by boiling in loading buffer for 30 rain. Ali- 
quots representing equivalent cell numbers (',,5  ×  106 cells)  were then 
separated on 8 % SDS-polyacrylamide gels and transferred to Immobilon 
membranes. Monkey kidney CV-1 extracts were prepared by lysing approxi- 
mately  1  ×  107  cells  in  lysis  250  buffer,  subjecting  extracts  to  three 
freeze/thaw  (liquid nitrogen/37*C)  cycles  and clearing by centrifugation 
(14K, 2 min at room temperature). Immunoprecipitates were separated by 
SDS-PAGE, and Western blotted. Various tissues from 2-mo-old mice were 
ground using a mortar and pestle under liquid nitrogen. The samples were 
then extracted in lysis buffer containing 250 mM NaC1, 50 mM Tris-HCI 
(pH 7.5), 0.125% Na-dcoxycholate, 0.375% Triton X-100, 0.15% NP-40, 4 
mM EDTA,  10 mM aprotinin, 50 mM leupeptin, and 1 mM PMSE After 
one freeze/thaw cycle,  the lysates were cleared as described above.  The 
same amount of total protein from each tissue was subsequently used for 
immunoprecipitation and immunoblotting analysis. 
For all Western blots, following addition of the appropriate primary anti- 
body and an alkaline phosphatase-conjngated secondary antibody, bound 
protein  was  visualized  with  5-bromo-4-chloro-3-indolylphosphate  to- 
luidinium and nitro blue tetrazolium (BCIP, NBT; Promega Biotec, Madi- 
son, WI). 
Cell Cycle Synchronization 
and Co-Immunoprecipitation 
CV-1 cells were synchronized to early (31, mid-S, and mid-M phase of the 
cell cycle. Lovastatin was used at 40 mM for 48 h to arrest the cells in early 
(31. A double block of hydroxyaa'ea, followed by a 5-h release, synchronized 
cells to mid-S phase. Mitotic cells were collected by shake-off following a 
24-h exposure to  1.0/~g/mi  nocodazole.  At each time point,  cells were 
washed twice with PBS and immediately lysed as described previously 
(Chela et al.,  1989). Following four freeze/thaw cycles and centrifugation 
at  14K for  10  min at 4"C,  supernatants were immunoprecipitated  with 
mAbs to RB protein (llDT) or p84 (5El0). Protein A-Sepharose was used 
to pellet the immunocomplexes.  After extensive washing in L250 buffer, 
samples were boiled for 5 min in SDS sample buffer. Complexes were sepa- 
rated by 8%  SDS-PAGE;  immunoblotting was done with liD'/and 5El0 
mAbs. 
lmmunocytochemistry and Image Analysis 
CV1 cells were fixed either in cold methanol for 10 min at -20°C,  or in 
4% formaldehyde prepared in cytoskeletal buffer (CSK; 0.01 M Pipes, pH 
6.7,  100 mM NaC1,  300 mM sucrose,  1.0 mM EGTA, 3 mM MgCI2) for 
30 min at room temperature. Formaldehyde-fixed cells were permeabilized 
in CSK containing 0.5% Triton X-100 for 5 min either prior to fixation, or 
afterwards. All three fixation protocols yielded similar staining patterns. All 
antibody and washing solutions were made in 0.1  M  Tris-HCl,  pH 7.4, 
0.15 M  NaC1,  0.1%  Tween-20,  5%  (wt/vol) dry milk,  and 0.1%  sodium 
azide. Co-localization of pll0  ~  and p84 was performed using a polyclonal 
rabbit anti-pll0  ~  antibody (0.47) mixed with the 5El0 IgG mAb to p84; 
the  respective antigens were  visualized  with goat anti-mouse IgG con- 
jugated  to  Texas  red  and  goat  anti-rabbit  conjugated  to  FITC.  Co- 
localization of p84 with an IgM mAb to the B1C8 nuclear matrix antigen 
(generously provided by S. Penman, Massaehnsetts Institute of Technology, 
Cambridge, MA; Wan et al.,  1994), which localizes to sites involving in 
RNA processing (snRNP- and SC35-positive speckles;  Blencowe et al., 
1994), was performed by mixing both primary antibodies as above, followed 
by goat anti-mouse IgG (Texas red) and goat anti-mouse IgM (FITC). The 
Sm human autoantibody sera (kindly provided by P. Sharp, Massachusetts 
Institute of Technology) was detected with goat anti-human IgG (FITC). 
Controls included omission of the primary antibody, and in the case of p84, 
5El0  mAb was  pre-incuhated  with excess  GST-N5  fusion protein  (not 
shown).  Confocal optical sections were obtained with a Zeiss 310 LSM, 
equipped with Ar and HeNe lasers.  Digital images of FITC or Texas red 
fluorescence, or of Normarski differential interference contrast, were over- 
laid for multichannel recording. Co-localization was performed either by 
the LSM software, or by merging the individual channels from a single Z 
section with VoxelView-ULTRA 2.1 and VoxelMath 2.0 software (Vital- 
Images,  Inc.,  Fairfield,  IO).  Intensity-hased thresholding was performed 
with the multi-channel rendering capability of VoxelView-ULTRA 2.1. All 
images were kernel filtered (N  =  3) by VoxelMath 2.0 using an average 
smoothing operation.  Pseudo-color tables, contrast and opacity were op- 
timized for each channel, before merging and thresholding, to visualize low 
levels of fluorescence. 
Nuclear Matrix Preparation 
The procedure of He et al.  (1990) was followed as described, except that 
antipain, leupeptin, and aprotinin (l-/zg/ml each), and sodium fluoride (5 
mM), were added to all extraction solutions. 
Results 
Isolation of cDNAs Encoding  p110  RB 
Amino-terminal-binding Proteins 
To screen for proteins able to bind the amino-terminal re- 
gion of pll0 ~,  a modified version of the yeast two-hybrid 
system was utilized (Durfee et al.,  1993). In this assay,  co- 
transformants of a yeast strain, Y153, which are phenotypi- 
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for  Gal4-RB  fusion  and 
screening  results.  (,4) Struc- 
tures of RB and yeast expres- 
sion vector. Bar represents the 
RB coding sequence with en- 
coded  protein  domains  and 
amino  acid coordinates  indi- 
cated.  The region  (encoding 
amino acids  1-300)  fused to 
the  Gal4  DNA-binding  do- 
main  is  bracketed,  and  the 
map of the resulting  expres- 
sion  vector,  pAS/N-RB,  is 
shown.  (B) Summary  of the 
screening  and  rescreening 
results.  The number of total 
transformants  was  estimated 
by plating an aliquot of each 
transformant  on  media  se- 
lecting only for the presence 
of the plasmids  (SC-trp-leu). 
The  approximate  number of 
His  +  positive  colonies  was 
determined  following plating 
of the transformation  on SC- 
trp-leu-his  +  25  mM  3-AT. 
The presence  of/3-galactosi- 
dase activity was detected us- 
ing the colony filter lift meth- 
od  (Breeden  and  Nasmyth, 
1985). N-RB dependency was 
determined  by  transforming 
Y153 with the isolated library- 
derived plasmid  alone or to- 
gether with either pAS/N-RB, 
pASRB2, or pAS/SNF1. Acti- 
vation domain-tagged hybrids 
which  interacted  specifically 
with  the  Gal4-N-RB  fusion 
only  were  counted  as  posi- 
fives. 
cally His  + and blue following the selection-screening proce- 
dure,  are considered as positives, and further assessed for 
their reproducibility and dependence on RB protein expres- 
sion. A yeast expression plasmid, pAS/N-RB, containing RB 
eDNA  encoding  the  first 300  amino  acids  of the  protein 
fused in-frame to sequences for the Gal4 DNA binding do- 
main was used to transform Y153  (Fig.  1 A).  A  resulting 
transformant  was  then  co-transformed with  an  activation 
domain-tagged human eDNA library created in the hACT 
vector (Durfee et al.,  1993). Of the approximately one mil- 
lion transformants tested, 21  were phenotypically His  + and 
blue in the initial screen, and six of those were reproducible 
and  dependent  on presence of pAS/N-RB,  as  shown in  a 
rescreen using purified plasmids (Fig.  1 B). Sequence data 
eliminated four of these clones as encoding either a cytoplas- 
mic protein or short peptides translated from eDNA in the 
reverse orientation. The remaining two clones, N5 and N11, 
encode the same gene whose protein product bound strongly 
to  the  amino-terminal  domain  of pll0  RB.  This  gene  was 
characterized further. 
A Structurally Defined Amino-terminal Domain of 
pllO  ~ Is Required for N5 Binding 
To define the sequences of the RB protein needed for binding 
N5, a series of amino-terminal mutations were created and 
subcloned into pAS1.  These mutants were then used to co- 
transform Y153  with N5-expressing plasmid DNA, and the 
resulting colonies were analyzed for/3-galactosidase activity 
(Fig. 2). Deletion mutants which affect a structurally defined 
amino-terminal domain (amino acids 8-262; Hensey et al., 
1994), abolished N5 binding. In addition, a linker insertion 
mutant (pAS/N-HBg), resulting in a 5-amino acid insert at 
residue 76, also blocked the ability of the RB protein to in- 
teract with  N5.  However, another linker  insertion  mutant 
(pAS/N-EBg) at position 181  had no effect on N5 associa- 
tion. Thus, a largely intact domain in the NH2 terminus is 
required for interaction and a small perturbation caused by 
an insertion at amino acid 76 can block this binding.  The 
Pvu-C mutant, which contains RB protein sequences from 
246-928 and binds T-ag in this system (data not shown), does 
not bind the N5 protein. 
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color  -~alar, lardamt 
Gal4 DBD 
N-Rb (1-300)  "/111/  blue  17.5 +  0.2 
N-HE (del 76-181)  ~'fll/Jm~i-"'"~  white  0.7 + 0.2 
N-BP (1-246)  "fllf/  white  0.4 _+ 0.1 
N-BE (1-181)  r/Ill,  I  white  0.5 + 0.2 
N-HR (76-300)  ¢////f""~  white  0.4 + 0.I 
4v,  pLg. 
N-HBg (ins 76)  rl///,,  white  0.5 _+. 0.2 
..__~Lhg.P 
N-EBg (ins 181)  "/,¢///-  blue  44.1 _+. 23.7 
Pvu.C (246-928)  ~'/lll,41111111~.lllllllllllllll  white  0.4 + 0.1 
All Gal4-RB fusions were expressed,  as determined  by immunoblotting  (data not shown). Colony color 
lift assay. CPRG quantitation  of/3-galactosidase  activity was done in triplicate  for each transformation. 
Figure 2. Detection of  interac- 
tions between N5 and RB mu- 
tants in vivo. The Gai4 DNA 
binding domain  (amino acids 
1-147; striped  box)  fused  to 
various RB mutants is shown 
schematically.  RB  amino 
acids present in the fusion are 
denoted, except in the case of 
linker insertions  (ins) and an 
internal deletion (del), where 
the  affected  amino  acid(s) 
within the N-RB fragment are 
indicated.  Inserted  amino 
acids are shown in single let- 
ter code.  Y153 was co-trans- 
formed  with  the  indicated 
panel of Gal4-RB mutants and 
the  N5  expression  plasmid. 
was determined by the colony 
NS-encoded Protein Binds pllO  ~  In Vitro 
The ability of the N5-encoded protein to bind native full- 
length RB protein was tested using an in vitro binding assay. 
The cDNA fragment present in the N5 clone was fused to 
sequences  for glutathione  S-transferase (GST) (Smith and 
Johnson,  1988) present on an E.  coli expression vector to 
create GST-N5. The fusion protein was expressed and then 
bound to an affinity matrix. The resulting complex was then 
incubated with cell extracts from a RB reconstituted WERI 
cell line, 3G10 (Chen et al., 1992). Complexes were washed, 
separated by SDS-PAGE, and immunoblotted with an anti- 
RB protein mAb. Fig. 3 shows that RB protein was retained 
in the GST-N5 column, comparable to the amount bound to 
the positive control column, GST-T-ag.  No significant bind- 
ing was seen in the GST column (Fig. 3). N5 also binds pref- 
erentiaUy to the hypophosphorylated form of the RB protein 
(Fig.  3),  analogous to T-ag binding (Ludlow et al.,  1989). 
Together, these data demonstrate that the N5-encoded pro- 
tein  can  bind  full-length  pll0  ~  and  this  association  is 
specific for the hypophosphorylated pll0  ~  isoform. 
Analysis of N5 Sequence 
Northern blot analysis using the N5 cDNA as a probe shows 
the mRNA for this gene to be ~2.1  kb in length (data not 
shown). To obtain a full-length eDNA clone of this gene, a 
human lymphocyte eDNA library (Elledge et al.,  1991) was 
screened, and several overlapping clones were isolated. The 
resulting 2,100-nucleotide  (nt) sequence has a  single large 
open reading frame (nt  15-1985)  which can encode an ex- 
tremely acidic (pI  =  4.85)  657 amino acid protein with a 
predicted molecular weight of 75,633  D  (Fig. 4).  The pre- 
dicted protein has no significant homology with any protein 
in the present databases. The ATG at nt  15 has a canonical 
purine  in the  -3  position  (Kozak,  1989),  and thus  likely 
serves as the  initiator codon;  however, the lack of an up- 
stream in-frame stop codon, together with the unknown na- 
ture of additional 5' sequences, prevents its unambiguous as- 
signment.  The  107-nt  3'  untranslated  region  contains  a 
canonical poly adenylation site,  AAUAAA,  followed by a 
polyA tail. 
Placing the  N5  fragment isolated in the original  screen 
within this sequence limits the region of the encoded protein 
necessary  for pll0  ~  binding.  Sequencing  reveals that the 
original N5 fragment spans nucleotides  1,132-2,066  of the 
near full-length cDNA,  and encodes amino acids 374-657 
Figure 3. In vitro binding of N5 and pll0  ~. Glutathione S-trans- 
ferase (GST) and in-frame GST fusions with eDNA encoding N5 
and the NH2-terminal 273 amino acids of T-antigen (GST-T) were 
expressed  in  E.  coli. GST  and  GST  fusions  were  bound  to 
glutathione-sepharose beads and washed extensively. Samples were 
quantitated  by Coomassie  blue staining  of SDS-PAGE gels  and 
equivalent protein amounts used in each lane. Extracts made from 
3GI0 cells (Cben et al., 1992) were mixed with the bound samples 
for 30  min at room temperature.  Following extensive  washing, 
complexes were separated by SDS-PAGE and transferred for immu- 
noblotting. The amount of RB protein present and the extent of its 
phosphorylation in 3(310 cells was determined by immunoprecipi- 
tation with the 11D7 antibody (lane 1). The blot was probed with 
an anti-RB protein monoclonal antibody,  11D7, and visualized by 
enzymatic color reaction. 
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GGCCTTCGTCGAAGATGTCTCCGAcGCCGCCGCTCTTCAGTTTGCCCGAAGCGCGGACGCGGTTTACGAAGTcTACCAGAGAG~CCTTGAACAACAAAAA  1~ 
MSPTPPLFSLPEARTRFTKSTREALNNKN 
CATCAAGCCATTGTTAAGTACCTTCAGCCAGGTAcCTGGCAGTGAAAATGAAAAAAAA~GTACC~T~GACCAAGCTTT~AGAGG~ATTC~AGAA~AAGAA  200 
IKPLLSTFSQVPGSENEKKCTLDQAFRGILEEE 
ATTATAAATCATTCATCATGTGAAAACGTTTTAGCTATTATTTCT~TTGCTATTGGGGGAGTAACTGAAGGTATTTGTACCGCATCTACA~CTTTTGTAT  3~ 
IINHSSCENVLAIISLAIG~VTEGICTASTPFV 
TGTTGGGAGATGTTTTGGATTGTCTTCCTTTGGATC~TGTGACACAATATTCACTTTTGTCGAAAAAAAT~TT~T~TTGGAAATCAAATAC~TTCTA  4~ 
LLGDVLDCLPLDQCDTIFTFVEKNVATWKSNTFY 
TGCTGcTGGGAAAAATTACTTACTACGTATGTGCAATGATCTCCTAAGAAGATTGTCTAAAT~CCAGAATACAGTCTTCTGTGGACGGATTCAGCT~TTT  500 
A  A  G  K  N  Y  L  L  R  M  C  N  D  L  L  R  R  L  S  K  S  Q  N  T  V  F  C  G  R  I  O  L  F 
TTGG~CAGGCTTTTCCCTCTGTCTGAGAAATCAGGTCTTAACTTG~AGAGTCAGTTTAATCTGGAAAATGTCACTGTTTTCAATACAAATGAGCAGGAAA  600 
LARLFPLSEKSGLNLQSQFNLENVTVFNTNEOE 
GCACCCTGGGTCAGAAGCACACTGAAGATAGAGAAGAAGGAAT~ATGTAGAAGAAGGCGAAATG~GAGATGA~AAG~TCCAACAA~GT~CTCTATTCC  7~ 
STLGOKHTEDREEGHDVEE~EMGDEEAPTTCSIP 
AATTGATTACAACCTGTATCGAAAATTCTGRTCACTTCAGGATTACTTCA~GAACCcTGTGcAATGCTATGAGAAGATTTCATGGAAAACTTTTCTCAAG 8~ 
IDYNLYRKFWSLODYFRNPVOCYEKISWKTFLK 
TATT~TGAA~AA~TTTTAGCTGTTTTTAA~AGTTATAAATTA~ATGAT~TCAGGCCTCAAGAAAAAAGATG~AAGAATTGAAAACAGGAGGAGAACAT~  900 
YSEEVLAVFKSYKLODTOASRKKflEELKTGGEH 
TATATTTTGCAAAATTTTTAACAAGTGAAAAGCTGATGGATTTACAACTGAGTGACAGTAACTTTCGTCGACACATCcT~TTGCAGTATCTCATTTTATT  1000 
VYFAKFLTSEKLMDLOLSDSNFRRHILLOYLILF 
CCAATATCTCAAGG~GCAGGTCAAATTCAAAA~TTCAAACTAT~TTTTAACTGATGA~CAATCACTTTGGATT~AAGATAc~ACAAAATCAGTTTATCAA  11~ 
OYLK~OVKFKSSNYVLTDEOSLWIEDTTKSVYO 
CTACTATCTGAAAACCCCCCC~AT~GAGAAAGATTTTCAAA~ATG~TAGA~CATATATTAAACACTGAAGAAAACTGGAACT~GTG~AAAAATGAAGGTT  12~ 
LLSENPPDGERFSKMVEHILNTEENWNSWKNEG 
GCCCAAGTTTTGTGAAAGAAA~AACATCAGATACCAAACCTACGAGAATAATTCGGAAGAGAAcAGCACCCGAGGACTTCCTAGGGAAAGGACCCAcCAA  1300 
CPSFVKERTSDTKPTRIIRKRTAPEDFLGK~PTK 
AAAAATTCTGAcGGGAAATGAGGAGTTAACAAGGCTTTGGAATCTTTGCCCTGATAATATGGAAGCC~GTAAATCAGAGA~AAGGGAACACA~CCCACT  I~ 
KILTGNEELTRLWNLCPDNMEACKSETREHMPT 
TTGGAG~AATTCTTTGAAGAAGCCATTGAACAGGCAGACCCTGAAAATATGGCGGAAAATGAATATAAGGCTATGAACAATTCAAATTATGGTTGGAGAG  15(]0 
LEEFFEEAIEOADPENHAENEYKAMNNSNYGWR 
CCCT~AAACTATTA~CA~GA~AAGC~CTCACTTCTT~CA~cCAACCAACCAG~AGTTTAAAAGTTTA~AA~AA~ATCTTGAAAATATG~TAATAAAGCT  1600 
ALKLLARRSPHFFOPTNOOFKSLOEYLENMVIKL 
AGCCAAGGAATTACC~cCT~CTTCTGAA~AAATAAAAAcAGGT~AGGATGAA~ATGA~GAAGATAATGATGCTCTACTGAAGGAAAATGAAA~TcCTGAT  17~ 
AKELPPPSEEIKTGEDEDEEDNDALLKENESPD 
GTTcGGC~AGACAAACCTGTAACAGGA~AACAAATAGAGGTATTTGCCAACAA~TGGGTGAACAATG~AA~ATTCTGGCTCC~TACTTGGAAATGAAAG  18® 
VRRDKPVTGEOIEVFANKLGEQWKILAPYLEMK 
ACTCAGAAATTAGG~AGATTGAGTGTGACAGTGAA~ACATGAAGATGAGAGCTAA~AGCTCCT~TT~CCTG~CAAGATCAA~AG~GAGTTCATGCAAC  Ig(]O 
DSEIRQIECDSEDMK~RAKOLLVAWODQEGVHAT 
A~CTGAQAATCTGATTAATG~ACTGAATAA~T~T~ATTAA~T~ACCTTQCA~AAA~CTAACTAAT~ACAAT~AGACAAATAGTTAGCTTCTTTTTTTT  2000 
PENLINALNKSGLSDLAESLTNDNETNS 
TTCTTTTTATTAAAA~TGT~ATA~ATTTT~TTA~AA~CAG~ATTTGATAA~AG~TCCACTG~TTTT~GTAAA~-~ATTTTTATAA~AAAAAAAA  21® 
B 
XbaI  Sail  EcoRI 
374  657 
Rb binding 
Figure  4.  Nucleotide  and 
predicted  amino  acid  se- 
quence of full-length N5.  (,4) 
Amino acids are shown in sin- 
gle letter code, and the first in- 
frame stop codon is indicated 
with an asterisk. The polyade- 
nylation signal, AAUAAA, is 
boxed.  (B)  Schematic of the 
full-length  N5  sequence. 
cDNA  is depicted  as a  line, 
with the p84 coding region in- 
dicated with a black bar. The 
pll0  RB  binding  domain  is 
overlaid on the coding region 
as a hatched box. Nucleotide 
and  amino  acid  coordinates 
are  shown  above  and below 
the  sequence,  respectively. 
The  asterisk  represents  the 
polyadenylation  signal, and the 
poly A  tail is  shown as A,. 
These sequence data are avail- 
able  from  EMBL/GenBank/ 
DDBJ under accession num- 
ber L36529. 
The Journal of Cell Biology, Volume 127, 1994  614 (Fig. 4 B), a highly negatively charged region of the protein. 
That  this  region  binds  to  the  pll0  RB amino-terminal  do- 
main, which is itself slightly acidic, may suggest hydropho- 
bic interactions are involved. 
Anti-N5 Antibodies Detect an 84-kD Protein from 
Mammalian Cells 
The GST-N5 fusion protein was used as an antigen to im- 
munize mice and generate polyclonal antibodies. The result- 
ing antisera specifically detected the GST-N5 antigen pro- 
duced in E. coli (data not shown). The ability of the antisera 
to recognize the N5 polypeptide was further demonstrated 
using  yeast  extracts  producing  the  Gal4  activation  do- 
main-N5 fusion. A polyclonal antibody, aN5-3, recognizes 
a  protein of the correct molecular weight only in the N5- 
expressing cells (Fig. 5 A, lanes 4-6).  No protein was de- 
tected with preimmune  serum (lanes  1-3).  In  addition,  a 
monoclonal antibody, 5El0, generated from the same anti- 
gen, produced identical results (lanes 6--9). 
To identify the authentic N5 protein in mammalian cells, 
CV-1 cell extracts were prepared and used for immunopre- 
cipitation with either the t~N5-3  antibody or controls. Im- 
munoprecipitates were  separated  by SDS-PAGE,  and  im- 
munoblotted with the 5El0 mAb (Fig. 5 B). The antibody 
recognizes an 84-kD protein from these cells which is lack- 
ing in the precipitates of both the preimmune  serum and 
those of an irrelevant anti-mouse IgG (compare lanes 1-3). 
Depletion of the ctN5-3  serum by preincubation with the 
GST-N5 fusion protein abolishes recognition of the 84-kD 
protein; incubation with GST alone or GST-R5N (containing 
the N5 sequences in reverse orientation) has no effect (lanes 
4 and 5). Thus, the anti-N5 antibodies specifically detect an 
84-kD protein from mammalian cells, in reasonable agree- 
ment with the predicted molecular weight from sequence 
data.  Therefore, this protein will be referred to as p84 for 
the remainder of this report. 
p84 Is a Nuclear Protein That Co-localizes with pllO  RB 
The cellular localization of p84 was determined by confocal 
immunofluorescence microscopy. CV-1 cells were fixed by 
several methods (see Materials and Methods), reacted with 
the 5El0 antibody and subsequently visualized via a fluores- 
cently labeled secondary antibody. All fixation methods re- 
vealed p84 to be localized within t~e nucleus (Fig. 6), con- 
sistent  with the  subcellular localization of pll0  ~  (Lee et 
al.,  1987). p84 is organized into multiple discrete foci and 
is not detected in the nucleolus (Fig. 6). An identical result 
was obtained with the c~N5-3 antibody (data not shown). To 
assess the amount of colocalization of Rb and p84 in the nu- 
cleus, the distribution of  both proteins in double labeled cells 
were assessed using the VoxelView-ULTRA and VoxelMath 
visualization  software  packages  (Vitallmages,  Inc.).  The 
opacity, contrast, and color tables were identically adjusted 
for each set of images to maximize visualization of low level 
fluorescence.  When  the  full  range  (100%)  of  detected 
fluorescence was rendered individually, it was clear that Rb 
(Fig. 7 a, green)  was more widespread in the nucleus than 
p84 (Fig. 7 b, red); however, many hot spots of Rb did over- 
lap with punctate spots of p84 (Fig. 7 c, yellow).  In an effort 
Figure 5. Anti-N5 antibodies specifically detect an 84-kD protein 
from mammalian cells. (A) Characterization of anti-N5 antibodies. 
Yeast cell extracts were made from Y153 (lanes 1, 4, and 7), Y153 
transformed with pSE1107 (Durfee et al., 1993) (lanes 2, 5, and 8), 
or Y153 transformed with N5  (lanes 3,  6, and 9), separated by 
SDS/PAGE, and immunoblotted. Lanes 1-3 were probed with pre- 
immune mouse serum, lanes 4-6 with a mouse anti-N5 polyclonal 
serum, aN5-3, and lanes 7-9 with a monoclonal antibody, 5E10, 
derived from aN5-3.  Reacting proteins were visualized by enzy- 
matic color reaction. (B) Detection of endogenous N5 protein from 
mammalian cells. CV-1 ceils were lysed, and subjected to immuno- 
precipitation with antibody preparations as indicated. Preabsorp- 
tion of the serum was performed as described  in Materials and 
Methods. Precipitates were separated by SDS-PAGE, and prepared 
for immunoblotting. Blots were probed with 5El0, and visualized 
by enzymatic color reaction. 
to assess,  and visualize, the amount of Rb that colocalized 
with p84, we used thresholding (based upon intensity) to re- 
move all but the top 10% of both channels (Fig. 7, d-f). The 
top  10%  Rb signal (Fig. 7 d, green)  and the top 10% p84 
signal (Fig. 7 e, red) were largely confined to overlapping 
or adjacent regions (Fig. 7f, yellow). It is interesting to note 
that some regions of mutually exclusive label is seen for both 
proteins. 
p84 Co-localizes to Nuclear Domains Involved in 
RNA Processing 
Specific regions of the nucleus that are rich in molecules in- 
volved in RNA metabolism have been identified (for recent 
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localization  of p84.  The anti- 
p84  Mab  5El0  was  used  to 
immunolabel  unsynchronized 
CV-1  cells  which  were  pre- 
extracted  with  0.5%  Triton-X 
100 in CSK buffer for 3 min. A 
representative  confocal  optical 
section of p84 fluorscence was 
merged with a differential inter- 
ference  contrast  image.  Note 
the  numerous  intranuclear 
speckles  and that nucleoli  are 
negative. Bar, 10/zm. 
reviews see Spector,  1993; and Xing and Lawrence,  1993). 
To determine whether the p84 speckles are coincident with 
these  RNA  processing  centers,  or  "transcript  domains" 
(Carter et al.,  1991;  Xing and Lawrence,  1993),  we used 
both the Sm autoimmune sera and a novel IgM mAb (B1C8) 
for colocalization with the 5El0 IgG mAb. The Sm autoim- 
mune sera labels multiple bright speckles in the nucleus, and 
a low level of homogeneous staining as well (Spector, 1993), 
which is attributed to recognition of several small nuclear 
ribonuclear  proteins  (snRNPs)  involved  in  splicing.  The 
B1C8 mAb identifies a  180-kD nuclear matrix protein (Wan 
et al.,  1994) that principally colocalizes with the bright foci 
labeled by the anti-SM antibody and the SC35 mAb (Fu and 
Maniatis,  1990),  and co-immunoprecipitates exon-contain- 
ing RNA from in vitro splicing reactions (Blencowe et al., 
1994).  SC35 is an essential non-snRNP splicing factor pre- 
Figure 7. Regions of high pll0  Ra 
concentration  colocalize  with 
p84.  Methanol-fixed  CV1  cells 
double  labeled  with  p84  mAb 
5E10 and rabbit anti-pll0  ~  anti- 
body 0.47. Confocal optical sec- 
tions of  both fluorescent channels 
were individually recorded.  The 
full spectrum (100%) of fluores- 
cent signals are shown in A-C; by 
thrcsholding  out  all but the top 
10%  of the  signals  in  D-F,  in- 
tranuclear  regions  of  intense 
staining for both proteins is high- 
lighted.  For each set of images, 
the opacity, contrast and color ta- 
bles were identically adjusted to 
maximize detection  of low level 
fluorscence.  (.4) p110  gs labeling 
(green)  appears  widely  dis- 
tributed  within this plane of nu- 
cleus, with frequent brighter foci 
throughout.  (B)  p84  (red)  ap- 
pears much more punctate.  (C) Colocalization  of pll0  ~  and p84 is apparent at multiple hot spots (yellow)  in this merged image. (D) 
Distribution  of the highest fluorescent intensity (concentration)  of pll0  ~  (green)  is significantly more confined to specific regions. (E) 
Removing 90% of the p84 image (red) results in a similar pattern of intranuclear speckles as in 8. (F) Areas containing high concentration 
of p110  ~  overlap, or are adjacent,  with the focal staining of p84 (yellow). Bar, 5 t~m. 
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Sm  antigen.  A  methanol-fixed 
CV1 cell was double labeled with 
mAb 5El0 and the Sm autoanti- 
body sera.  The highest concen- 
tration of both p84 (A, red) and 
the Sm antigen (B, green) is found 
in a similar intranuclear speckled 
pattern. The Sm antigen is some- 
what more diffuse in the nucleo- 
plasm compared with p84. When 
the Texas Red and FITC channels 
are overlaid,  regions of colocal- 
ization appear as yellow (C). The 
colocalization  results  are  su- 
perimposed  with  cellular  mor- 
phology in D (in this case, B1C8 
is assigned as blue). Bar, 25 #m. 
viously shown to colocalize with snRNP antigens  (Fu and 
Maniafis, 1990; Spector et al., 1991), poly-adenylated RNA 
(Carter et al.,  1991),  and specific gene transcripts (Huang 
and Spector, 1992; Carter et al.,  1993). Fig. 8 shows the re- 
sult of colocalization experiments using the 5El0 mAb (Fig. 
8 a, red) and the Sm sera (Fig. 8 b, green). When these chan- 
nels were merged, the majority of the punctate labeling pat- 
tern appears as yellow (Fig.  8 c), indicating a high degree 
of overlap within the optical section. Fig. 8 d shows the p84 
(red) and Sm (in this image, shown as blue) fluorescent sig- 
nals overlaid with a differential interference contrast image 
(green) of the cell morphology. The resulting image shows 
the colocalization as purple, and indicates the relative posi- 
tion of these antigens against the nuclear morphology. These 
data strongly support the idea that p84 is abundant in centers 
associated with RNA processing. 
As the relatively insoluble B1C8 nuclear matrix antigen is 
more specifically confined to regions of RNA processing as 
compared to the  Sm antigen,  i.e.,  highly  coincident with 
Sc35 (Blencowe et al.,  1994) we performed double-labeling 
experiments with 5El0 (IgG) and B1C8 (IgM) mAbs on CV1 
cells briefly preextracted with detergent. When 100 % of the 
Figure 9. p84 colocalizes with the 
BlC8  nuclear matrix antigen.  A 
CV1  cell  that  was  briefly  pre- 
extracted with 0.5 % Triton X-100 
was fixed and labeled with mAbs 
to p84 (IgG) (A and D, red); and 
the BIC8 (IgM) nuclear  matrix/ 
spliced  RNA-binding  antigen 
(Wan et  al.,  1994) (B  and  E, 
green).  A-C  shows images  in 
which  the  full  range  (/00%)  of 
collected pixels values are repre- 
sented. Images in D-F represent 
only the top 1% (by intensity) of 
each channel.  The colocalization 
(yellow)  of  p84  and  B1C8  is 
shown in C and F  Note that  in 
both the 100 and 1% panels, p84 
and B1C8 are largely overlapping. 
Interestingly,  there  are  areas 
where these  antigens  are mutu- 
ally exclusive (red only or green 
only). Bar, 5 #m. 
Durfee et al. N-Domain of Rb Binds an 84-kD Nuclear Matrix Protein  617 signal in cells double labeled with p84 (Fig. 9 a, red) and 
the B1C8 antigen (Fig. 9 b, green) are superimposed, a high 
degree of alignment is readily apparent (Fig. 9 c, yellow). As 
an indication of  the degree of colocalization between p84 and 
B1C8 based upon fluorescent intensity, when both channels 
were reduced to just 1% of the highest recorded signal, the 
pattern of labeling of p84 (Fig. 9 d, red) and B1C8 (Fig. 9 
e, green) still remained largely overlapped (Fig. 9f, yellow). 
However, as with other matrix antigens found largely within 
RNA processing domains (Blencowe et al., 1994) there are 
instances where both proteins are mutually exclusive (red or 
green  in Fig.  9  d).  It remains to be determined if these 
smaller, p84-positive speckles represent sites of transcrip- 
tion, identified by Br-UTP incorporation, that are not found 
associated with intensely staining, SC35-rich domains (Wan- 
sink et al.,  1993). 
Figure 10. Localization of nuclear matrix-bound p84. (A) Staining 
pattern of p84 in the nuclear matrix prepared by sequential in situ 
extraction  with  Triton  X-100,  RNase-free DNaseI, 0.25 M 
(NI-h)SO4, and 2 M NaCI (He et al., 1990). Th~ strong punctate 
staining remains following  the removal  of 70% of the soluble pro- 
teins and 95% of  the DNA (He et al., 1990). The BIC8 antigen (B, 
green) also remains associated with the matrix almost all regions 
containing p84 (C, yellow). Bar, 5/zm. 
p84 IS a Component of the Nuclear Matrix 
During G1, hypophosphorylated wild type p110  RB has been 
shown to resist low-salt/detergent extraction (Mittnacht and 
Welnberg,  1991) and  associate  with  the  nuclear  matrix 
(Mancini et al.,  1994).  Further, pll0  ~  binds in vitro to the 
nuclear matrix proteins, lamins A and C  (Mancini et al., 
1994;  Shan  et  al.,  1992).  Tumor-derived RB  mutations, 
which affect the binding of the viral oncoprotelns (Tag, ET, 
and E1A), do not associate with the matrix (Mittnacht and 
Weinberg,  1991; Templeton et al.,  1991; Mancini et al., 
1994),  nor does an lib protein with a deletion from the sec- 
ond T/E1A domain through the carboxyl terminus bind to 
lamin A in vitro (Mancini et al., 1994). These data strongly 
suggest a  functional importance to the association pll0  aB 
with the nuclear matrix. In an effort to identify additional nu- 
clear matrix proteins that bind the RB protein, we have rou- 
tinely examined putative pll0RB-binding  proteins for their 
affinity to the nuclear matrix.  Accordingly, we tested the 
ability of p84 to withstand not only brief exposure to deter- 
gent (Figs. 6 and 9), but a thorough regiment of well-estab- 
lished extraction procedures that gently reveal the nonchro- 
matin, insoluble system of core filaments and fibrogranular 
components comprising the nuclear matrix (He et al., 1990). 
This procedure removes greater than 85 % of nuclear pro- 
teins and 95 % of the DNA, leaving behind the core filament- 
containing nuclear matrix (He et al.,  1990).  Fig.  10 is a 
panel of images that show p84  (Fig.  10 a,  red)  and B1C8 
(Fig.  10 b, green) remain predominantly colocalized (Fig. 
10 c, yellow) in discrete loci following matrix isolation. A 
small amount of p84  is  still visibly outside the B1C8 foci 
(Fig.  10 c, red). 
To verify the immunostaining data on extracted cells, the 
5El0 mAb and immunoblot analysis was used to examine the 
protein composition of sequential supernatants from the ex- 
tractions, and the 2  M  salt-resistant, insoluble nuclear ma- 
trix pellet. Fig. 11 shows that the extraction procedure, dur- 
ing both Gj and S phases, does not effectively release p84, 
as most of the protein is found in the final, insoluble pellet. 
The confocal immunofluorescence images suggest that p84 
localizes to many foci within the matrix (Fig. 10); however, 
high-resolution ultrastructural localization studies will be 
necessary to specifically identify the structures that contain 
p84. Nevertheless, the in situ localization and the biochemi- 
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CV-1 cells were cell cycle arrested in either G~ by lovastatin (lanes 
1-5), or in mid-S by blocking twice with hydroxyurea followed by 
a 5-h release (lanes 6-10), and then subjected to the extraction pro- 
cedure. Whole cell lysates were compared with the extracted mate- 
rial from each step and the final pellet by SDS-PAGE separation, 
and immunoblotting with the 5El0 antibody. In both the G1 and S 
phase cells, most of the p84 is found in the final insoluble nuclear 
matrix pellet (lanes 5 and 10).  Blots were probed with 5El0,  and 
visualized by enzymatic color reaction. 
cal fractionation data support the conclusion that p84 is a 
component of the nuclear matrix. 
Tissue Distribution of  p84 
To investigate the expression pattern of p84, extracts were 
made from various organs of an adult mouse and immuno- 
precipitated with the 5El0 mAb. Irnmunoprecipitates were 
then separated by SDS-PAGE and irnmunoblotted.  As seen 
in Fig.  12, p84 is expressed in each tissue examined analo- 
gous  to  pll0  ~  (Lee  et  al.,  1987).  Similar  experiments 
using various human cell lines confirm the ubiquitous  ex- 
pression of p84 in humans as well (data not shown).  Thus, 
p84 and pll0  ~  have the same wide tissue distribution indi- 
cating their interaction may have a role in regulating a basic 
function(s) of either or both proteins. 
p84 Co-immunoprecipitates with pllO  ~  in a Cell 
Cycle-dependent Manner 
To demonstrate that the p84/p110  ~  association can occur at 
physiological concentrations, and to determine the timing of 
the interaction more precisely, co-immunoprecipitation ex- 
periments using CV1 ceils were conducted. Cultures of CV1 
cells were synchronized either in G~, S, or M phases of the 
cell cycle by addition of appropriate drugs. Direct lysis with 
300  mM  salt,  followed by  several cycles of freezing and 
thawing, effectively solubilizes p84 and pll0  ~.  Extracts of 
these  cultures  were then  immunoprecipitated by the  anti- 
p110  ~  mAb, 11D7 (Shun et al.,  1992) or 5E10.  After exten- 
sive washing,  precipitates  were separated by SDS-PAGE, 
and immunoblotted with either llD'/or 5EI0. p84 is detected 
in  the  11D7 immunoprecipitates from G~  cells  (Fig.  13), 
consistent with its association with the hypophosphorylated 
form of pll0  ~  (Fig.  3).  The very low level of hypophos- 
phorylated  pll0  ~  present  in  nocodozole-arrested  cells 
(Ludlow et al.,  1993),  makes detection of any association 
during this time point unlikely. No association was observed 
during S phase (Fig.  13).  This cell cycle dependency is not 
due to altered p84 expression as the 5E10 immunoprecipi- 
tates indicate the protein is present at approximately equiva- 
lent  levels in  GI,  S,  or M  phase (Fig.  13).  These results 
demonstrate the interaction is specific for the hypophosphor- 
ylated  form of pll0  ~  and  confirms the  GST-N5  binding 
Figure 12.  Tissue distribution  of the p84 protein.  Tissue samples 
were obtained  from an adult mouse, and used to prepare cell ex- 
tracts.  12.5/zg of total protein per sample was separated by SDS- 
PAGE, and immunoblotted  using the anti-N5 mAb, 5El0.  Bound 
protein  was detected by enzymatic color reaction. 
Figure 13.  Cell cycle timing of the p84/p110  as association.  CV-1 
cells were synchronized by treatment with Lovastatin (lanes 1 and 
2), a double block with hydroxyurea and a 5-h release (lanes 3 and 
4), or nocodazole (lanes 5 and 6). Cells were then lysed, and im- 
munoprecipitated with either the anti-RB protein monoclonal anti- 
body,  liD'/(lanes 2, 4, and 6), or the anti-p84 monoclonal  anti- 
body, 5El0 (lanes 1, 3, and 5). Precipitates were then separated on 
an 8%  SDS-polyacrylamide gel, and transferred  to Imrnobilon. 
One portion of the blot was probed with 111217, while the other was 
probed  with  5El0.  llD7  mAb to pll0  ~  co-immunoprecipitates 
p84 only during GI. Bound protein was detected by enzymatic color 
reaction. 
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munoprecipitates is likely due to antibody interference with 
the interaction. 
Discussion 
We have used the yeast two-hybrid system to screen for cellu- 
lar proteins that interact with the amino-terminal 300 amino 
acids of the RB protein. In contrast to the carboxy-terminal 
region of p110  ~  which interacts with multiple cellular pro- 
teins (Kaelin et al.,  1991; Lee et al.,  1991), only a  single 
clone was isolated which associates with the amino-terminal 
fragment. The gene encodes a novel nuclear protein of 657 
amino acids with a predicted molecular weight of 75 kD; 
however, when separated on SDS-polyacrylamide gels, the 
native protein isolated from human, monkey, and mouse 
cells  migrates  more  slowly with  an  apparent  molecular 
weight of 84 kD. This nuclear protein, p84, is expressed in 
all tissues examined and throughout the cell cycle, analogous 
to p110  ~  (Lee et al.,  1987).  Clues to the function of p84 
come from our immunological and biochemical experiments 
which  demonstrate that it  is  concentrated in  subnuclear 
regions known to be involved in RNA processing. Further, 
similar to many critical molecules involved in the  splic- 
ing/transcription machinery, p84 is a component of the nu- 
clear matrix. As with other proteins which bind the RB gene 
product, p84 preferentially interacts with the hypophosphor- 
ylated isoform ofpll0  ~, and does so predominantly during 
G1, the time when pll0  ~  is functionally active (Goodrich 
et al., 1991) and associates with the nuclear matrix (Mancinl 
et al., 1994).  We cannot rule out that some interaction be- 
tween p84 and Rb protein may occur during late M phase 
when hypophosphorylated p110  ~  accumulates, p84, there- 
fore, in addition to lamins A and C (Mancini et al., 1994; 
Shan et al., 1992),  represents a potential site of interaction 
for p110  ~  on the matrix. 
The nuclear matrix has been implicated in most metabolic 
activities occurring in the nucleus,  including replication, 
transcription,  and RNA  splicing and transport  (Berezney 
and Coffey, 1975; Ciejek et al., 1983; Zeitlin et al., 1989). 
Many of the molecular components responsible for these ac- 
tivities have been identified as either constitutively or tran- 
siently associated matrix proteins. We have shown that p84 
colocalizes with the intranuclear speckles labeled by the Sm 
autoantibody, which is often used to identify sites of RNA 
splicing (Spector, 1993). Further, p84 and the more punctate 
B1C8 nuclear matrix antigen (Wan et al.,  1994) colocalize 
in both whole nuclei and on the matrix. B1C8 also colocal- 
izes with essential components (snRNPs, SC35) of the RNA 
splicing centers (Blencowe et al., 1994).  These splicing do- 
mains are also found to contain, or be adjacent to, sites of 
specific gene transcription (Huang and Spector, 1991; Xing 
et al.,  1993).  Taken together, the localization data suggest 
a role for p84 in one or more of  these functions as well. Con- 
sidering that most p84 foci either overlap or are adjacent 
with "hot spots"  of pll0  ~, p84 may also function to con- 
centrate a portion of the RB protein to these regions. AS im- 
munogold labeling  of both  nuclear  matrix-bound p110  ~ 
(Mancinl et al., 1994) and B1C8 (Wan et al., 1994) are local- 
ized to the fibrogranular masses by resinless section electron 
microscopy, it is highly probable that p84 will also, thus 
identifying the sub-matrix location where p110~/p84 inter- 
actions would occur. Direct resinless section electron micro- 
scopic colocalization of pll0  ~  with p84, and other compo- 
nents of the splicing/transcript domains, will be required to 
substantiate this hypothesis. 
During G1, studies indicate that low-salt/detergent extrac- 
tion leaves some hypophosphorylated RB protein "tethered 
to the nuclear structure" (Mittnacht and Weinberg,  1991); 
mutant RB proteins do not display this property (Mittnacht 
and Weinberg, 1991; Templeton et al., 1991). A portion of 
wild-type hypophosphorylated pll0  ~  can  also  withstand 
the stringent conditions necessary to reveal the nuclear ma- 
trix (Mancini et al., 1994).  Does binding to p84 contribute 
to p110  ~  matrix association during the cell cycle? Whereas 
the amount of matrix-bound p84, and its subnuclear organi- 
zation, appears normal in tumor cells containing RB muta- 
tion (Mancini, M. A,, and W.-H. Lee, unpublished results), 
the fact that mutant RB protein does not tether to the matrix 
(Mittnacht and Weinberg,  1991; Templeton et al.,  1991; 
Mancini et al.,  1994)  suggests that COOH-terminal mu- 
tations may affect binding to p84.  Alternatively, the p84/ 
pll0  ~  interaction may not be sufficient for matrix associa- 
tion. Experiments to address this issue are underway. 
The mechanism whereby pll0RB exerts a  growth sup- 
pressing affect upon cells is not yet fully understood. How- 
ever,  several  studies  have  clearly  demonstrated  that  the 
carboxy-terminal half of the RB protein is essential,  and 
when overexpressed, sufficient for this activity (for review 
see Goodrich and Lee, 1993; Hinds et al., 1992).  Evidence 
now indicates that, in the context of the full-length protein, 
the amino-terminal domain is also required for growth sup- 
pression (Qian et al.,  1992),  and the recent isolation of an 
RB  mutation  affecting only  this  domain  from  a  retino- 
blastoma tumor (Hogg et al.,  1993),  further supports this 
conclusion. These results indicate that the amino-terminal 
domain provides a function which is essential under phys- 
iological conditions, but which can be  bypassed through 
mass action of the carboxy-terminal region alone. What is 
the function of  the amino-terminal domain and how does p84 
binding affect it? As the highest concentrations of p84 are 
found in regions of the nucleus associated with splicing fac- 
tors (Spector,  1993) and specific gene transcription (Huang 
and Spector,  1991; Carter et al., 1993;  Xing et al.,  1993), 
p84  association could  focus a  subset  of pll0  ~  to  these 
areas while still allowing important interactions to occur 
through  the  carboxy-terminal domains.  Association  with 
several transcription factors, most notably E2F (Helin et al., 
1992; Kaelin et al., 1992;  Shan et al., 1992),  through car- 
boxy-terminal sequences,  is  thought  to  be  essential  for 
pll0  ~  function. The additional p84  found outside the re- 
gions  labeled with  SC35  may also  colocalize with  sites 
of general transcription,  as  studies  reveal  many BrUTP- 
positive foci associate with less-intense regions of SC35- 
staining (Wansink et al., 1993; Jackson et al., 1993). Local- 
ization of pll0  ~  to RNA processing centers is consistent 
with the relatively high RB protein concentrations found in 
areas of low DNA density (Szekely et al.,  1991), i.e., the 
transcriptionally active euchromatin, and its proposed role 
in the regulation of several transcription factors. Thus, as- 
sociation with p84 would be an efficient  means of concentrat- 
ing the RB protein to subnuclear regions where active forms 
of several target-associated proteins (transcription factors) 
would be located. 
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regulatory affect on a carboxy-terminal function(s) through 
either inter- or intramolecular interactions. This hypothesis 
is supported by two lines of evidence indicating that the ter- 
tiary  structure  of pll0  ~  is severely compromised by small 
alterations  in its amino-terminal region.  First,  such muta- 
tions  dramatically  affect  the  ability  of the  protein  to  be 
hyperphosphorylated (Hamel et al., 1990; Qian et al., 1992; 
Hinds et al., 1992), considered to be an important indicator 
of the structural integrity of the RB protein. Second, amino- 
terminal  mutants  also disrupt interaction with the carboxy- 
terminal half of p110  RB (Hensey et al., 1994), an interaction 
that appears  to be required for oligomerization (Hensey et 
al., 1994).  Mutations with such dramatic  consequences for 
pll0  Rs  structure  are  likely  to  interfere  with  its  function 
and/or regulation. As p84 interacts  specifically with the ac- 
tive form of pll0  ~,  this association may be a mechanism 
for removing an inhibitory effect by the NH2-terminal  do- 
main upon the active carboxy-terminal region. However, this 
switch would be reversible allowing pll0  RB to be inactivated 
when cell division was required. 
A highly complex and interactive mechanism for p110  ~- 
mediated  tumor  suppression  is  suggested  by the  multiple 
proteins it binds, and the spatially  and solubility based sub- 
nuclear compartmentation of pll0  ~  itself. Does the associ- 
ation of pll0 ~  with both matrix-bound and soluble binding 
partners,  particularly  within regions associated with RNA 
processing, represent a unique mechanism whereby the RB 
protein exerts  its  tumor suppressing  activity?  To fully ad- 
dress this question, future studies must examine these inter- 
actions in the context of the full-length RB protein, and how 
it interfaces with architecturally  based partitioning  of nu- 
clear metabolism. 
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